RIGL
$26.38
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibito...
Recent News
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.
Rigel Pharmaceuticals Inc (RIGL) Q4 2025 Earnings Call Highlights: Record Net Income and ...
Rigel Pharmaceuticals Inc (RIGL) reports a remarkable increase in net income and outlines future growth strategies amidst a strong financial performance in Q4 2025.
How The Rigel Pharmaceuticals (RIGL) Story Is Shifting With New Targets And Pipeline Progress
Rigel Pharmaceuticals is back in focus as analysts update their narrative around the stock, with the fair value price target holding steady at $51.6. Supportive voices point to this unchanged figure as a sign that, despite tweaks to the underlying model, confidence in Rigel Pharmaceuticals' long term potential remains intact, while more cautious views question how dependent this target is on ambitious revenue and margin assumptions. As you read on, you will see how different analysts are...
Rigel Pharma (RIGL) Earnings Call Transcript
Also with me are David A. Santos, our Chief Commercial Officer; Lisa Rojkjaer, our Chief Medical Officer; and Dean L. Schorno, our Chief Financial Officer. On today's call, I will provide an overview of Rigel Pharmaceuticals, Inc.'s business, our accomplishments for the fourth quarter and full year 2025, as well as our strategic initiatives to drive growth. Beginning on slide four, I will outline Rigel Pharmaceuticals, Inc.'s transformational growth strategy in hematology and oncology.
Rigel Pharmaceuticals Q4 Earnings Call Highlights
Rigel Pharmaceuticals (NASDAQ:RIGL) detailed record commercial performance for the fourth quarter and full year 2025, while outlining plans to pursue additional in-licensing opportunities and advance its lead pipeline candidate, R289, in lower-risk myelodysplastic syndromes (MDS). 2025 marked a shi